Related Experiment Video
Updated: May 16, 2026
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Dendritic cell therapy for Type 1 diabetes suppression
Nick Giannoukakis1, Massimo Trucco
1Department of Pathology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Rangos Research Center, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Abstract:
While dendritic cell-based therapy is a clinical reality for human malignancies, until now, some conceptual concerns have served to delay its consideration to treat human autoimmune diseases, even in light of almost two decades' worth of overwhelmingly supportive preclinical animal studies. This article provides an overview of the development of dendritic cell-based therapy for Type 1 diabetes mellitus, given that this is the best-studied autoimmune disorder and that there is a good understanding of the underlying immunology. This article also highlights data from the authors' pioneering Phase I clinical trial with tolerogenic dendritic cells, which hopes to motivate the clinical translation of other dendritic cell-based approaches, to one or more carefully selected Type 1 diabetic patient populations.
Insights
Dendritic cell therapy shows promise for autoimmune diseases like Type 1 diabetes. A Phase I trial using tolerogenic dendritic cells offers hope for clinical translation in diabetic patients.
Area of Science:
- Immunology
- Cell Therapy
- Endocrinology
Background:
- Dendritic cell (DC)-based therapy is established for cancer treatment.
- Conceptual barriers have hindered DC therapy for autoimmune diseases despite preclinical evidence.
- Type 1 diabetes mellitus (T1DM) is a well-understood autoimmune disorder ideal for studying DC-based approaches.
Purpose of the Study:
- To review the development of DC-based therapy for T1DM.
- To present findings from a pioneering Phase I clinical trial using tolerogenic DCs.
- To encourage broader clinical translation of DC-based therapies for T1DM.
Main Methods:
- Overview of DC-based therapy development for T1DM.
- Presentation of data from a Phase I clinical trial involving tolerogenic DCs.
- Focus on immunological understanding relevant to T1DM.
Main Results:
- The article highlights the potential of DC-based therapies in autoimmune contexts.
- Pioneering Phase I clinical trial data with tolerogenic DCs is presented.
- Supportive preclinical animal studies spanning nearly two decades are acknowledged.
Conclusions:
- Tolerogenic DC therapy represents a promising avenue for T1DM treatment.
- Clinical translation of DC-based approaches for T1DM is feasible and warrants further investigation.
- This work aims to inspire further clinical trials and applications of DC therapy in autoimmune diseases.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
01:12Type I Diabetes I: Introduction
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type II Diabetes I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:40Cell-mediated Immune Responses